Menu Search
Equities

Novartis AG

NOVNEE:SWX

Novartis AG

Actions
  • Price (CHF)86.17
  • Today's Change0.20 / 0.23%
  • Shares traded500.00k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Jun 18 2021 15:44 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		NOVN:SWX since
announced		Transaction
value
Cadent TherapeuticsAnnounced17 Dec 202017 Dec 2020Announced6.46%770.00m
Vedere Bio IncDeal completed30 Sep 202030 Sep 2020Deal completed6.48%280.00m
Data delayed at least 15 minutes, as of Jun 18 2021 16:31 BST.

Institutional shareholders

0.00%Per cent of shares held by top holders
HolderShares% Held
Pyrford International Ltd.as of 30 Jun 2020269.16k0.00%
LUKB Expert Fondsleitung AGas of 31 Jan 202132.69k0.00%
AQR Capital Management LLCas of 31 Mar 20205.54k0.00%
Niederer & Partners AGas of 30 Jun 20185.30k0.00%
Sabadell Asset Management SA SGIIC SUas of 30 Jun 20201.04k0.00%
Majedie Asset Management Ltd.as of 15 Nov 2020474.000.00%
CA Indosuez Wealth (Private Banking Europe)as of 30 Jun 2020336.000.00%
Margetts Fund Management Ltd.as of 31 Jul 20200.000.00%
More ▼
Data from 30 Jun 2018 - 31 Mar 2021Source: FactSet Research Systems Inc.
Refinitiv, an LSEG business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.